Background Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe
coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in …

Background A subset of patients with COVID-19 develops a hyperinflammatory syndrome
that has similarities with other hyperinflammatory disorders. However, clinical criteria …

Background A better understanding of the epidemiology and clinical features of invasive
fungal infection (IFI) is integral to improving outcomes. We describe a novel case-finding …

Pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) is associated with
poor outcomes and frequently merits empirical antibiotic consideration despite its relatively …

Background Community-acquired pneumonia (CAP) guidelines have improved the treatment
and outcomes of patients with CAP, primarily by standardization of initial empirical therapy. …

Question Is broad-spectrum antibiotic use associated with poor outcomes in community-onset
pneumonia after adjusting for confounders? Methods We performed a retrospective, …

Importance Evidence on the effectiveness and safety of COVID-19 therapies across a diverse
population with varied risk factors is needed to inform clinical practice. Objective To assess …

Background Neutralizing monoclonal antibodies (MAbs) are a promising therapy for early
coronavirus disease 2019 (COVID-19), but their effectiveness has not been confirmed in a real-…

Clostridioides difficile infection (CDI) is a health care-associated infection associated with
significant morbidity and cost, with highly varied risk across populations. More effective, risk-…

The health care-associated pneumonia (HCAP) criteria have a limited ability to predict
pneumonia caused by drug-resistant bacteria and favor the overutilization of broad-spectrum …